Aetna Ozempic or Wegovy Denied? GLP-1 Appeal Guide

Aetna, the CVS Health-owned insurer serving tens of millions of Americans, has become one of the most restrictive major payers when it comes to GLP-1 receptor agonist medications like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide). These drugs — originally developed for type 2 diabetes and now FDA-approved for chronic weight management — sit at the center of a coverage battle between patients, physicians, and insurers over how obesity is classified and whether treatment for it constitutes medical necessity. Aetna's coverage framework draws a sharp distinction based on the specific FDA indication: Ozempic (type 2 diabetes) is generally covered with step therapy; Wegovy and Zepbound (weight management) face categorical exclusions under many employer plans. That distinction, and how to challenge it, is the foundation of a successful appeal.

Why Insurers Deny GLP-1 Claims

Aetna denies GLP-1 prescriptions for several recurring reasons:

• Diabetes vs. weight management indication — Aetna generally covers semaglutide as Ozempic for type 2 diabetes but excludes semaglutide as Wegovy for weight management under general obesity drug exclusions; tirzepatide faces similar exclusions when prescribed as Zepbound rather than Mounjaro
• Step therapy not completed for diabetes — Even for members with type 2 diabetes seeking Ozempic, Aetna's CVS Caremark pharmacy benefit imposes step therapy requiring metformin and often a sulfonylurea before authorizing a GLP-1; if prior drug trials are not documented with dates, dosages, and reasons for failure, the PA is denied
• Categorical obesity drug exclusion — Many employer self-funded ERISA plans exclude "weight loss drugs" or "obesity treatment" entirely; these exclusions are increasingly contested under ACA Section 1557 non-discrimination provisions for fully insured plans and under ADA arguments recognizing obesity as a chronic disease
• BMI criteria not met under CPB 0618 — Aetna's CPB 0618 establishes BMI thresholds for weight management drug coverage; verify the specific BMI criteria in your plan's benefit design
• Cardiovascular comorbidities not documented — The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events in obese patients without diabetes; documenting cardiovascular disease, hypertension, sleep apnea, or prediabetes transforms the claim from "cosmetic weight loss" to medically necessary cardiovascular risk reduction
• State step therapy reform law not applied — Most states have enacted step therapy reform laws requiring an exception process when a required step agent is contraindicated, previously failed, or clinically inappropriate; Aetna must honor these exemptions under applicable state law for fully insured plans

How to Appeal

Step 1: Identify the Denial Type and Plan Type

Determine whether the denial is for a diabetes-indicated GLP-1 (Ozempic, Mounjaro) or a weight management-indicated GLP-1 (Wegovy, Zepbound), and whether your plan is fully insured or self-funded. Call Aetna Member Services to obtain the complete clinical criteria used in the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denial, including the specific step therapy protocol and CPB cited (CPB 0618 for weight management medications). For pharmacy denials through CVS Caremark, confirm whether the denial came from the pharmacy benefit or medical benefit — the appeal pathways differ.

Step 2: Request Peer-to-Peer Review

Your prescribing physician should request a peer-to-peer review with Aetna's medical director before or immediately after the denial. This is one of the most effective tools for overturning GLP-1 denials at the PA stage — the physician can explain why the prescribed medication is clinically necessary, why step therapy alternatives are inadequate, and why cardiovascular comorbidities make this a medically necessary intervention rather than a cosmetic one.

Step 3: Gather Supporting Documentation

1. Documentation of failed step therapy agents: medical records showing you tried required prior medications — dates, dosages, duration, reasons for failure (inadequate HbA1c control, intolerable side effects, contraindications)
2. Physician clinical letter addressing Aetna's specific GLP-1 prior authorization criteria: HbA1c levels, BMI, cardiovascular risk factors, and all comorbidities (cardiovascular disease, hypertension, sleep apnea, prediabetes)
3. FDA approval documentation and clinical trial evidence: LEADER and SUSTAIN trial data for cardiovascular benefit; SELECT trial data showing mortality reduction in obesity patients with cardiovascular disease — these arguments reframe the prescription as cardiovascular treatment
4. Comorbidity list and medical records documenting all obesity-related conditions
5. State step therapy reform law citation: most states have enacted laws requiring exceptions when required step agents are contraindicated, previously failed, or clinically inappropriate

Step 4: File the Internal Appeal

File a formal internal appeal in writing within 180 days under ACA §2719. Submit to Aetna's Pharmacy Appeals or Clinical Appeals Unit depending on whether the denial came from the pharmacy or medical benefit. Cite ACA §2719, ERISA §1133 (if employer plan), your state's step therapy reform law, and ACA Section 1557 (non-discrimination argument for categorical obesity exclusions in fully insured plans). For ERISA employer plans with categorical obesity exclusions, also explore a challenge through the DOL under ERISA's non-discrimination provisions.

Step 5: Pursue External Independent Review: Complete Guide" class="auto-link">External Review

If your appeal is denied, request an independent external review through your state's IRO under ACA §2719. Because GLP-1 approvals have evolved rapidly, external reviewers often apply more current medical standards than Aetna's CPB 0618. The IRO's decision is binding on Aetna. Simultaneously file a complaint with your state insurance commissioner if the denial involves a state step therapy reform law violation.

Step 6: File Regulatory Complaints

File with your state Department of Insurance (naic.org/state_web_map.htm) for step therapy law violations or discriminatory benefit design. For ERISA employer plans with categorical obesity exclusions, file with the DOL's Employee Benefits Security Administration at dol.gov/agencies/ebsa.

What to Include in Your Appeal

• Denial letter with specific CPB and step therapy protocol cited and Aetna CPB 0618 (from aetna.com/cpb)
• Documentation of failed step therapy agents (dates, dosages, reasons for failure, physician notes)
• Physician clinical letter with HbA1c levels, BMI, cardiovascular risk factors, and all comorbidities
• SELECT trial data and LEADER/SUSTAIN trial cardiovascular outcomes evidence
• State step therapy reform law citation and comorbidity medical records
• ACA Section 1557 non-discrimination argument for categorical obesity exclusions in fully insured plans

Fight Back With ClaimBack

GLP-1 denials from Aetna are among the most contested insurance battles of 2025 and 2026. The science has moved faster than Aetna's coverage policies, and CPB 0618's criteria often lag behind FDA approvals and cardiology guidelines. Many of these denials are won on appeal — particularly when the cardiovascular comorbidity record is strong and the step therapy arguments are clearly articulated. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal